<DOC>
	<DOCNO>NCT03044223</DOCNO>
	<brief_summary>The present study focus patient Pseudomonas aeruginosa ( PSA ) sepsis . The aim present study find whether M1 ( pro-inflammatory ) M2 ( anti-inflammatory ) phenotype predominate blood monocyte critically ill patient PSA-sepsis , whether severity sepsis outcome associate distinct monocyte phenotype function .</brief_summary>
	<brief_title>Monocyte Profiles Critically Ill Patients With Pseudomonas Aeruginosa Sepsis</brief_title>
	<detailed_description>During bacterial related sepsis , one key play cell macrophage , monocytes T-lymphocytes ( Hotchkiss et al. , 2003 ) . Macrophages monocyte suppose essential septic reaction Gram-negative bacteria ( Hotchkiss et al . 2003 ) . Generally , two dominant type macrophage : pro-inflammatory M1 macrophage anti-inflammatory M2 macrophage ( Mantovani et al. , 2006 ) . Similar macrophage characteristic , monocyte also categorize pro-or anti-inflammatory . These macrophage/monocyte phenotype differentiate vitro freshly isolated human blood monocyte use either GM-CSF give raise M1 macrophage/monocyte M-CSF result M2 macrophage/monocyte ( Mantovani et al. , 2006 ; Neu et al. , 2013 ) . Brunialti et al . ( 2012 ) already demonstrate population antiinflammatory M2 monocytes septic patient big pro-inflammatory M1 population . However , author analyze underlie mechanism M2 polarization identify sepsis-causing pathogen . In present study , monocyte macrophage patient Pseudomonas aeruginosa ( PSA ) sepsis characterize surface marker expression profile via flow cytometry cytokine pattern ELISA vivo ex-vivo LPS stimulation . In addition , ex-vivo model system PSA induce sepsis validate . Blood critically ill patient ICU infect PSA sample isolate peripheral blood mononuclear cell ( PBMCs ) . Blood monocytes analyzed surface marker expression determine relative proportion M1 M2 monocytes patient healthy control flow cytometry</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<criteria>age &gt; 18 year critically ill patient sepsis microbiologically proven infection Pseudomonas aeruginosa life expectancy &lt; 24 hour participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pseudomonas aeruginosa</keyword>
	<keyword>critically ill patient</keyword>
	<keyword>sepsis</keyword>
	<keyword>monocyte</keyword>
	<keyword>macrophage</keyword>
	<keyword>cytokine</keyword>
	<keyword>severity disease</keyword>
</DOC>